Nexstim Supports 6th International Symposium on Navigated Brain Stimulation in Neurosurgery
HELSINKI, October 2, 2014 /PRNewswire/ --
Nexstim Oy ("Nexstim" or the "Company"), a medical technology company aiming to improve rehabilitation for stroke patients through the use of noninvasive brain stimulation, announces its support for the 6th International Symposium on Navigated Brain Stimulation in Neurosurgery to be held in Berlin on 10-11 October 2014.
With growing acceptance of Navigated Brain Stimulation (NBS) for pre-operative cortical mapping for patients with brain tumors or other brain diseases, the symposium will feature a hands-on demonstration of Nexstim's recently-launched NBS 5 system, the latest version of the first and only FDA-cleared and CE-marked navigated Transcranial Magnetic Stimulation (TMS) device for pre-surgical mapping of the motor and speech cortices.
Sessions on pre-surgical motor and speech mapping will look at the application of navigated TMS and navigated repetitive TMS techniques whilst the final session will cover the therapeutic use of Nexstim's technology for stroke, called Navigated Brain Therapy (NBT®), and in other potential applications including pain and tinnitus. The symposium is run by Charité-Universitätsmedizin Berlin and Technische Universität München.
Nexstim's CEO, Janne Huhtala, said: "Nexstim is pleased to support this important symposium. We continue to develop our exciting technology for diagnostics and therapy across a variety of applications."
Please Note: Nexstim´s NBS System is cleared by the FDA for assessment of the motor and speech cortices for pre-procedural planning. The NBT® System is not cleared for commercial distribution in the United States.
About Nexstim
Nexstim is a medical technology company aiming to improve rehabilitation for stroke patients. Nexstim has pioneered its technology in brain diagnostics with the Navigated Brain Stimulation (NBS) system as the first and only FDA-cleared and CE-marked navigated Transcranial Magnetic Stimulation (nTMS) device for pre-surgical mapping of the motor and speech cortices. Based on the same technology platform the company has developed a device for stroke therapy, called Navigated Brain Therapy (NBT®). Nexstim has initiated a two-year pivotal Phase III study at 12 sites in the US aiming to demonstrate the effectiveness of NBT® and gain FDA clearance for commercialisation in post-acute stroke therapy in the US.
About Transcranial Magnetic Stimulation (TMS) and Repetitive Transcranial Magnetic Stimulation (rTMS)
Transcranial Magnetic Stimulation (TMS) is a noninvasive technique that consists of a magnetic field emanating from a wire coil held outside of the head. The rapidly changing magnetic field induces a stimulating electric field in the brain. In repetitive Transcranial Magnetic Stimulation (rTMS) the coil delivers a rapidly pulsed magnetic field in order to modulate cortical function in a region of the brain.
About Navigated Brain Stimulation (NBS)
Navigated Brain Stimulation is a noninvasive technique that allows accurate and detailed mapping of the critical motor and speech functions of the cortex. Through the use of a standard MRI brain scan, transcranial magnetic stimulation, and EMG, the NBS mapping stimulates areas of the cortex and records motor responses.
About Navigated Brain Therapy (NBT®)
Using MRI-based guidance, Navigated Brain Therapy (NBT®) is a novel technique that can be used to accurately target noninvasive rTMS to the cortical structures believed to be involved in brain dysfunction. The NBT® System is CE-marked for use in patients recovering from motor stroke as a supplement to conventional rehabilitation.
For more information, please contact:
Nexstim
Janne Huhtala, Chief Executive Officer
+358-40-8615046
janne.huhtala@nexstim.com
Consilium Strategic Communications
Mary-Jane Elliott
Amber Bielecka
Ivar Milligan
Laura Thornton
+44(0)20-3709-5700
nexstim@consilium-comms.com
SOURCE Nexstim Oy
Share this article